Clinical operations field note

How to Staff Phase 1 Oncology Trials

Evaluate Phase 1 oncology CTM and CRA readiness for dose escalation, evolving safety data, eligibility, and rapid protocol amendments.

By Lampgen Clinical Research

1 min read · estimated

Phase I oncology staffing
  1. EARLY-PHASE WORK MOVES FAST Protocol amendments, dose decisions, and emerging safety information can change priorities quickly.
  2. COMMUNICATION IS PART OF RISK CONTROL Slow escalation between sites, vendors, and the sponsor can affect more than a timeline.
  3. EXPERIENCE MUST MATCH THE STUDY Years in clinical research do not automatically equal readiness for dose escalation or complex oncology eligibility.
  4. THE RIGHT RESOURCE REDUCES THE LEARNING CURVE Phase I programs need CTMs and CRAs who understand the pace, ambiguity, and documentation discipline.

Phase I oncology does not allow a long adjustment period.

Teams may be managing evolving safety information, narrow eligibility criteria, dose-escalation decisions, protocol amendments, intensive site communication, and incomplete data at the same time.

That environment changes the staffing question.

The question is not simply whether someone has worked as a CRA or CTM. It is whether that person can operate when the study is moving quickly and the information is still developing.

Phase I oncology staffing should account for dose-escalation schedules, time-sensitive pharmacokinetic sampling, and safety escalation.

For early-phase staffing, relevance matters as much as tenure.

AVAILABLE FOR NEW PARTNERSHIPS

What does your clinical team need next?